The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Background:Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treat...

Descripción completa

Detalles Bibliográficos
Autores: Jimenez-Fonseca, P, Foy, V, Raby, S, Carmona-Bayonas, A, Macia-Rivas, L, Arrazubi, V, Lavin, DC, Gil, RHS, Custodio, A, Cano, JM, Montes, AF, Mirallas, O, Declara, IM, Tocino, RV, Visa, L, Limon, ML, Pimentel, P, Lago, NM, Sauri, T, Richard, MM, Mangas, M, Raga, MG, Calvo, A, Reguera, P, Granja, M, Carnicero, AM, Perez, CH, Cerda, P, Gonzalez, LG, Navalon, FG, Barcia, VP, Abad, D, Martin, MR, Weaver, J, Mansoor, W, Gallego, J
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p2267
Acceso en línea:https://i3pt.portalinvestigacion.com/publicaciones/2267
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85150526719&doi=10.1177%2f17588359231157641&partnerID=40&md5=7bd57a7cd686fe8d637feb9df728271b
Access Level:acceso abierto
Palabra clave:gastric cancer
HER2-positive
nomogram
oesophageal cancer
survival
trastuzumab
Descripción
Sumario:Background:Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab. Methods:Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included. The model was externally validated in an independent series (The Christie NHS Foundation Trust, Manchester, UK). Results:In all, 737 patients were recruited (AGAMENON-SEOM, n = 654; Manchester, n = 83). Median PFS and OS in the training cohort were 7.76 [95% confidence interval (CI), 7.13-8.25] and 14.0 months (95% CI, 13.0-14.9), respectively. Six covariates were significantly associated with OS: neutrophil-to-lymphocyte ratio, Eastern Cooperative Oncology Group performance status, Lauren subtype, HER2 expression, histological grade and tumour burden. The AGAMENON-HER2 model demonstrated adequate calibration and fair discriminatory ability with a c-index for corrected PFS/OS of 0.606 (95% CI, 0.578-0.636) and 0.623 (95% CI, 0.594-0.655), respectively. In the validation cohort, the model is well calibrated, with a c-index of 0.650 and 0.683 for PFS and OS, respectively. Conclusion:The AGAMENON-HER2 prognostic tool stratifies HER2-positive AGA patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints.

Similares en LA Referencia